The current state and future prospects of chronic hepatitis C virus infection treatment

Christopher Moore, Josh Levitsky*

*Corresponding author for this work

Research output: Contribution to journalArticle

9 Citations (Scopus)

Abstract

Hepatitis C virus (HCV) infection is a significant cause of chronic liver disease with substantial long-term sequelae. Until very recently, therapies to cure HCV were hindered by high nonresponse rates and severe side effects. The first-generation protease inhibitor-containing regimens provided superior cure rates for many HCV-infected patients, although their side-effect profile proved to be quite burdensome. We are now witnessing the emergence of therapies with superior cure rates, limited side effects, and broad genotypic activity. Two therapies, sofosbuvir (an NS5b polymerase inhibitor) and simeprevir (a second-generation NS3/4A protease inhibitor), were approved by the Food and Drug Administration in late 2013 for use in a number of HCV populations. This review focuses primarily upon these therapies and the key studies that support their use in practice. Furthermore, representative novel antiviral therapies, in advanced stages of testing, are also reviewed.

Original languageEnglish (US)
Article number413
JournalCurrent Infectious Disease Reports
Volume16
Issue number8
DOIs
StatePublished - Jan 1 2014

Fingerprint

Chronic Hepatitis C
Virus Diseases
Hepacivirus
Protease Inhibitors
Therapeutics
United States Food and Drug Administration
Antiviral Agents
Liver Diseases
Chronic Disease
Population

Keywords

  • Chronic liver disease
  • Cirrhosis
  • Direct-acting antiviral therapies
  • Hepatitis C virus
  • Interferon-free
  • Liver transplantation
  • Ribavirin
  • Simeprevir
  • Sofosbuvir

ASJC Scopus subject areas

  • Infectious Diseases

Cite this

@article{6c2f5e656f2c4612825ba60184b1caae,
title = "The current state and future prospects of chronic hepatitis C virus infection treatment",
abstract = "Hepatitis C virus (HCV) infection is a significant cause of chronic liver disease with substantial long-term sequelae. Until very recently, therapies to cure HCV were hindered by high nonresponse rates and severe side effects. The first-generation protease inhibitor-containing regimens provided superior cure rates for many HCV-infected patients, although their side-effect profile proved to be quite burdensome. We are now witnessing the emergence of therapies with superior cure rates, limited side effects, and broad genotypic activity. Two therapies, sofosbuvir (an NS5b polymerase inhibitor) and simeprevir (a second-generation NS3/4A protease inhibitor), were approved by the Food and Drug Administration in late 2013 for use in a number of HCV populations. This review focuses primarily upon these therapies and the key studies that support their use in practice. Furthermore, representative novel antiviral therapies, in advanced stages of testing, are also reviewed.",
keywords = "Chronic liver disease, Cirrhosis, Direct-acting antiviral therapies, Hepatitis C virus, Interferon-free, Liver transplantation, Ribavirin, Simeprevir, Sofosbuvir",
author = "Christopher Moore and Josh Levitsky",
year = "2014",
month = "1",
day = "1",
doi = "10.1007/s11908-014-0413-1",
language = "English (US)",
volume = "16",
journal = "Current Infectious Disease Reports",
issn = "1523-3847",
publisher = "Current Science, Inc.",
number = "8",

}

TY - JOUR

T1 - The current state and future prospects of chronic hepatitis C virus infection treatment

AU - Moore, Christopher

AU - Levitsky, Josh

PY - 2014/1/1

Y1 - 2014/1/1

N2 - Hepatitis C virus (HCV) infection is a significant cause of chronic liver disease with substantial long-term sequelae. Until very recently, therapies to cure HCV were hindered by high nonresponse rates and severe side effects. The first-generation protease inhibitor-containing regimens provided superior cure rates for many HCV-infected patients, although their side-effect profile proved to be quite burdensome. We are now witnessing the emergence of therapies with superior cure rates, limited side effects, and broad genotypic activity. Two therapies, sofosbuvir (an NS5b polymerase inhibitor) and simeprevir (a second-generation NS3/4A protease inhibitor), were approved by the Food and Drug Administration in late 2013 for use in a number of HCV populations. This review focuses primarily upon these therapies and the key studies that support their use in practice. Furthermore, representative novel antiviral therapies, in advanced stages of testing, are also reviewed.

AB - Hepatitis C virus (HCV) infection is a significant cause of chronic liver disease with substantial long-term sequelae. Until very recently, therapies to cure HCV were hindered by high nonresponse rates and severe side effects. The first-generation protease inhibitor-containing regimens provided superior cure rates for many HCV-infected patients, although their side-effect profile proved to be quite burdensome. We are now witnessing the emergence of therapies with superior cure rates, limited side effects, and broad genotypic activity. Two therapies, sofosbuvir (an NS5b polymerase inhibitor) and simeprevir (a second-generation NS3/4A protease inhibitor), were approved by the Food and Drug Administration in late 2013 for use in a number of HCV populations. This review focuses primarily upon these therapies and the key studies that support their use in practice. Furthermore, representative novel antiviral therapies, in advanced stages of testing, are also reviewed.

KW - Chronic liver disease

KW - Cirrhosis

KW - Direct-acting antiviral therapies

KW - Hepatitis C virus

KW - Interferon-free

KW - Liver transplantation

KW - Ribavirin

KW - Simeprevir

KW - Sofosbuvir

UR - http://www.scopus.com/inward/record.url?scp=84901726489&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84901726489&partnerID=8YFLogxK

U2 - 10.1007/s11908-014-0413-1

DO - 10.1007/s11908-014-0413-1

M3 - Article

C2 - 24893980

AN - SCOPUS:84901726489

VL - 16

JO - Current Infectious Disease Reports

JF - Current Infectious Disease Reports

SN - 1523-3847

IS - 8

M1 - 413

ER -